CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 62 filers reported holding CUE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,960 | -31.6% | 19,113 | +8.6% | 0.00% | – |
| Q2 2023 | $64,266 | +29.3% | 17,607 | +26.5% | 0.00% | – |
| Q1 2023 | $49,709 | +23.8% | 13,924 | -1.2% | 0.00% | – |
| Q4 2022 | $40,148 | +29.5% | 14,087 | +0.8% | 0.00% | – |
| Q3 2022 | $31,000 | -91.7% | 13,977 | -90.7% | 0.00% | – |
| Q2 2022 | $374,000 | -49.1% | 150,205 | -0.2% | 0.00% | – |
| Q1 2022 | $735,000 | -57.4% | 150,557 | -1.2% | 0.00% | – |
| Q4 2021 | $1,724,000 | -49.5% | 152,423 | -35.0% | 0.00% | -100.0% |
| Q3 2021 | $3,416,000 | -25.7% | 234,425 | -40.6% | 0.00% | 0.0% |
| Q2 2021 | $4,598,000 | -37.4% | 394,650 | -34.5% | 0.00% | -50.0% |
| Q1 2021 | $7,346,000 | +14.4% | 602,094 | +17.3% | 0.00% | 0.0% |
| Q4 2020 | $6,422,000 | +26.3% | 513,370 | +52.0% | 0.00% | +100.0% |
| Q3 2020 | $5,083,000 | -37.3% | 337,734 | +2.2% | 0.00% | -50.0% |
| Q2 2020 | $8,102,000 | +265.1% | 330,558 | +111.3% | 0.00% | +100.0% |
| Q1 2020 | $2,219,000 | +1409.5% | 156,421 | +1162.3% | 0.00% | – |
| Q2 2018 | $147,000 | – | 12,392 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |